Eagle Pharmaceuticals (EGRX) Competitors $1.96 0.00 (0.00%) As of 04/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock EGRX vs. GNLX, OPTN, ORMP, PLRX, XBIT, ALTS, MGNX, EXOZ, GALT, and ANIXShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Genelux (GNLX), OptiNose (OPTN), Oramed Pharmaceuticals (ORMP), Pliant Therapeutics (PLRX), XBiotech (XBIT), Janone (ALTS), MacroGenics (MGNX), Exozymes (EXOZ), Galectin Therapeutics (GALT), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Genelux OptiNose Oramed Pharmaceuticals Pliant Therapeutics XBiotech Janone MacroGenics Exozymes Galectin Therapeutics Anixa Biosciences Genelux (NASDAQ:GNLX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment. Does the MarketBeat Community prefer GNLX or EGRX? Eagle Pharmaceuticals received 396 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 65.71% of users gave Eagle Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGeneluxOutperform Votes16100.00% Underperform VotesNo VotesEagle PharmaceuticalsOutperform Votes41265.71% Underperform Votes21534.29% Do analysts rate GNLX or EGRX? Genelux currently has a consensus target price of $18.25, indicating a potential upside of 654.13%. Given Genelux's stronger consensus rating and higher probable upside, research analysts clearly believe Genelux is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GNLX or EGRX more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -105.05% -80.16% Eagle Pharmaceuticals N/A N/A N/A Which has preferable valuation & earnings, GNLX or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than Genelux. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$8K10,467.71-$28.30M-$0.96-2.52Eagle Pharmaceuticals$257.55M0.10$35.64MN/AN/A Does the media favor GNLX or EGRX? In the previous week, Genelux and Genelux both had 1 articles in the media. Genelux's average media sentiment score of 0.93 beat Eagle Pharmaceuticals' score of 0.00 indicating that Genelux is being referred to more favorably in the media. Company Overall Sentiment Genelux Positive Eagle Pharmaceuticals Neutral Which has more risk & volatility, GNLX or EGRX? Genelux has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Do institutionals and insiders hold more shares of GNLX or EGRX? 37.3% of Genelux shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 9.3% of Genelux shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryEagle Pharmaceuticals beats Genelux on 8 of the 15 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.46M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / Sales0.10241.49397.62103.30Price / Cash0.4065.8538.1834.62Price / BookN/A6.486.734.25Net Income$35.64M$143.41M$3.22B$248.18M7 Day Performance15.29%2.58%1.38%1.03%1 Month Performance26.45%5.00%2.79%2.70%1 Year Performance-55.45%-3.72%15.41%4.05% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle PharmaceuticalsN/A$1.96flatN/A-53.2%$25.46M$257.55M0.00100Analyst ForecastGNLXGenelux1.6367 of 5 stars$2.70+2.7%$18.25+575.9%-26.2%$93.43M$8,000.00-2.8410Upcoming EarningsNews CoverageOPTNOptiNose3.2582 of 5 stars$9.16-0.1%$9.00-1.7%-31.1%$92.26M$78.23M-2.18190Short Interest ↓News CoveragePositive NewsORMPOramed Pharmaceuticals1.2227 of 5 stars$2.25+4.7%N/A-3.0%$91.91M$1.34M20.4510Upcoming EarningsAnalyst UpgradePLRXPliant Therapeutics4.3024 of 5 stars$1.48+1.4%$13.31+799.5%-87.2%$90.85M$1.58M-0.4490Upcoming EarningsNews CoveragePositive NewsXBITXBiotech1.2647 of 5 stars$2.97+1.0%N/A-64.1%$90.55M$4.01M-2.75100Upcoming EarningsNews CoverageALTSJanoneN/A$5.56+8.0%N/AN/A$89.40M$12.53M0.00170News CoverageGap DownMGNXMacroGenics4.0071 of 5 stars$1.39+10.3%$7.38+430.6%-89.2%$87.70M$148.34M-0.88430Upcoming EarningsNews CoveragePositive NewsEXOZExozymesN/A$10.47-3.4%N/AN/A$87.61MN/A0.0029GALTGalectin Therapeutics1.2844 of 5 stars$1.31-5.1%$11.00+739.7%-62.9%$87.19MN/A-1.799ANIXAnixa Biosciences2.0516 of 5 stars$2.69-1.1%$9.00+234.6%-9.7%$86.61M$210,000.00-6.905 Related Companies and Tools Related Companies GNLX Alternatives OPTN Alternatives ORMP Alternatives PLRX Alternatives XBIT Alternatives ALTS Alternatives MGNX Alternatives EXOZ Alternatives GALT Alternatives ANIX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EGRX Stock Free EGRX Stock Alerts